Nanomerics wins the United Kingdom King’s Award for Enterprise - Innovation 2024
@TheKingsAwards
bit.ly/nmx_KAE2024
Nanomerics retweeted
We are honored to ring the closing bell on July 24th and recognize the hard work and outstanding contributions from our entire team. We have made tremendous progress in moving our product candidates forward and expect to be in human clinical trials in 2024.
lnkd.in/eJz78vY
lnkd.in/euPrJxMJ
#VRPX #pharma #pharmanews #pharmaindustry #painmanagement #CNS
Nanomerics retweeted
We are pleased to have been selected to present our MET platform to the science and technology staff at the Defense Threat Reduction Agency (DTRA), Defense Advanced Research Projects Agency (DARPA) in addition to members of the Army, Navy and other military branches and Federal agencies. lnkd.in/e7xUi9jJ
#VRPX #pharmaceuticals #pharma #pharmaindustry #CNS #pain
Nanomerics retweeted
Thanks @nanomerics for hosting participants on our #RSCBroadeningHorizons programme, which supports students from Black & minority ethnic backgrounds to launch a #ChemCareer, including Kholil Rahman, a postgraduate student at @OfficialUoM🧵 rsc.li/3MZjHV6
Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada
The patent together with others takes protection of Nanomerics' ocular Molecular Envelope Technology (MET) franchise, in Canada, to 2035
accesswire.com/viewarticle.a…
1
181
Nanomerics Awarded an MHRA Innovation Passport for OC134 accesswire.com/viewarticle.a…
Nanomerics retweeted
We applaud this recent statement by Dr. Robert Califf, FDA Commissioner, about supporting development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.
“We’ve continued to support development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices...
lnkd.in/g9FCYWau
Nanomerics developed NIH-backed nasal nonaddictive pain prospect clears early test fiercepharma.com/drug-delive…
Nanomerics CSO Ijeoma Uchegbu appointed to Wellcome's board @wellcometrust wellcome.org/news/ijeoma-uch…
4
Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology https://nitter.cf/t.co/xKWme9AAL6 @MDPIpharma #DrugDelivery
2
Nanomerics retweeted
Congratulations to our 50 new Fellows announced today
Find out more about these prominent biomedical and health scientists and see the full list on our website: ow.ly/nchU50EIJ0a
#AMSFellows2021
Nanomerics CSO Prof I F Uchegbu elected a fellow of the Academy of Medical Sciences @acmedsci https://nitter.cf/t.co/Rtmll1pnd0
3
Nanomerics receives double milestone payment from @VirpaxPharma for Envelta™️ and MMS019, an antiviral nasal spray accesswire.com/viewarticle.a….
Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication. Press release update with more details https://nitter.cf/t.co/SJN0dRyUxN #COVID19 #molecular_mask
Nanomerics retweeted
SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray biorxiv.org/cgi/content/shor… #bioRxiv
Original tween about our collaboration with the teams @JagiellonskiUni and @ucl
SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray biorxiv.org/cgi/content/shor… #bioRxiv
1
Nanomerics Molecular Mask Technology (MMT): SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray biorxiv.org/content/10.1101/…
Nanomerics receives pIND guidance from the US FDA for NM134 for the treatment of an undisclosed, potentially sight threatening eye disease. https://nitter.cf/t.co/UFYrwspWXv
2
Nanomerics retweeted
New paper in @MolPharmJournal: Molecular Envelope Technology - first demonstration of highly concentrated subcutaneous formulations with hyaluronidase coated nanoparticles. Encapsulated CUDC-101 successfully suppresses pancreatic cancer in tumour models. https://nitter.cf/t.co/n03NWIMDNL















